Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 May, 2015 06:40 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS | 19 Nov, 2012, 09.43AM
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).



Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
RBI removes restrictions on new FII investment in Ipca Lab - 22-May-2015 18:30
RBI raises FII investment limit in Somany Ceramics to 40% - 22-May-2015 18:20
ITC Q4 profit climbs 3.6%, misses forecasts - 22-May-2015 17:38
Karnataka Bank quarterly profit jumps 65.5% - 22-May-2015 15:50
Tata Motors launches PRIMA in Bangladesh - 22-May-2015 15:42
Tata Motors launches PRIMA in Bangladesh - 22-May-2015 15:42
Strides Arcolab turns to profit in Jan-Mar quarter - 22-May-2015 15:30
Punj Lloyd reports Rs 2.69 bn profit in Q4 - 22-May-2015 15:25
No order to recall Maggi Noodles being sold: Nestle India - 22-May-2015 15:19
SBI witnesses improvement in asset quality - 22-May-2015 14:24
Hi-Tech Gears Q4 profit surges 83.78% - 22-May-2015 14:02
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer